Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BCTX Stock Forecast 2026-2027
$3.70
Current Price
$32.19M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to BCTX Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
BCTX Price Momentum
+13.5%
1 Week Change
+20.5%
1 Month Change
-82.5%
1 Year Change
-48.0%
Year-to-Date Change
-87.7%
From 52W High of $30.00
+42.3%
From 52W Low of $2.60
📊 TOP ANALYST CALLS
Did BCTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if BriaCell is one of their latest high-conviction picks.
Latest BCTX Stock Price Targets & Analyst Predictions
BCTX has shown a year-to-date change of -48.0% and a 1-year change of -82.5%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for BCTX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BCTX Analyst Ratings
1
Buy
0
Hold
0
Sell
BCTX Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $3.70
Latest BCTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BCTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 27, 2025 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $40.00 |
| Apr 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 3, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 12, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 3, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 19, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Sep 11, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jun 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 24, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 28, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $18.00 |
| Oct 3, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $20.00 |
| Jun 28, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $25.00 |
| Feb 24, 2023 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $25.00 |
| Feb 14, 2022 | HC Wainwright & Co. | Emily Bodnar | Buy | Initiates | $25.00 |
BriaCell Therapeutics Corp. (BCTX) Competitors
The following stocks are similar to BriaCell based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BCTX
BriaCell
mkt cap
28.36M
BriaCell Therapeutics Corp. (BCTX) Financial Data
BriaCell Therapeutics Corp. has a market capitalization of $32.19M with a P/E ratio of -0.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -175.3%.
Valuation Metrics
Market Cap
$32.19M
Enterprise Value
$7.00M
P/E Ratio
-0.1x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+70.8%
Current Ratio
7.1x
Debt/Equity
0.0x
ROE
-175.3%
ROA
-90.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
BriaCell Therapeutics Corp. (BCTX) Business Model
About BriaCell Therapeutics Corp.
What They Do
Develops novel immunotherapies for cancer care.
Business Model
The company operates as a clinical-stage biotechnology firm that generates revenue through the development of targeted immunotherapies. It focuses on harnessing the immune system to combat various cancers, particularly metastatic breast cancer, with its lead candidate Bria-IMT currently in Phase 3 trials. Additionally, BriaCell is working on personalized and next-generation immunotherapy platforms, which may provide future revenue streams.
Additional Information
BriaCell has received Fast Track designation from the FDA, indicating its potential to address unmet medical needs in cancer treatment. The company also has a subsidiary, BriaPro Therapeutics Corp., which is engaged in creating binding agents and small-molecule oncology programs. This diversified approach aims to improve survival outcomes for cancer patients facing limited treatment options.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Dr. William V. Williams M.D.
Country
Canada
IPO Year
2010
Website
briacell.comBriaCell Therapeutics Corp. (BCTX) Latest News & Analysis
Latest News
Quick Summary
BriaCell Therapeutics has signed a Memorandum of Understanding with Uneedle to enhance the commercial readiness of Uneedle's microneedle technology for delivering Bria-IMT in metastatic breast cancer treatment.
Why It Matters
BriaCell's partnership with Uneedle enhances its drug delivery system for Bria-IMT, potentially improving treatment efficacy and marketability, which could drive stock performance and investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BriaCell Therapeutics reported positive Phase 2 data for Bria-IMT in metastatic breast cancer, showing 55% >1 year and 27% >2-year survival. Phase 3 study data will be presented at ASCO 2026.
Why It Matters
Positive Phase 2 data for Bria-IMT in metastatic breast cancer indicates potential for significant survival benefits, boosting investor confidence in BriaCell Therapeutics' future prospects and ongoing studies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BriaCell Therapeutics closed a best-efforts offering of 1,449,300 common shares at $3.25 each, raising approximately $4.7 million before fees. Shares are traded on Nasdaq and TSX.
Why It Matters
BriaCell's $4.7 million capital raise signals investor confidence and supports ongoing development in cancer immunotherapy, potentially enhancing its growth and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BriaCell Therapeutics is offering 1,449,300 common shares at $3.25 each, aiming for gross proceeds of about $4.7 million. The offering closes on June 2, 2026, pending customary conditions.
Why It Matters
BriaCell's share offering raises $4.7 million for funding, indicating investor confidence and potential for growth in the cancer therapy market, impacting stock valuation and market sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BriaCell Therapeutics received a sixth consecutive positive recommendation from the Data Safety Monitoring Board for its Phase 3 Bria-ABC study on Bria-IMT plus CPI in metastatic breast cancer.
Why It Matters
Positive recommendations from the Data Safety Monitoring Board indicate strong safety profiles for BriaCell's therapies, potentially boosting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
BriaCell Therapeutics will present positive clinical data from its Phase 3 study of Bria-IMT at the ASCO Annual Meeting, May 29–June 2, 2026, alongside additional Phase 2 analyses.
Why It Matters
Positive clinical data from BriaCell's presentations at ASCO can boost investor confidence, potentially driving stock prices higher and attracting interest in its cancer therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About BCTX Stock
What is BriaCell Therapeutics Corp.'s (BCTX) stock forecast for 2027?
Analyst forecasts for BriaCell Therapeutics Corp. (BCTX) are not currently available. The stock is trading at $3.70.
Is BCTX stock a good investment in 2027?
According to current analyst ratings, BCTX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BCTX stock?
Price predictions from Wall Street analysts for BCTX are not currently available. The stock is trading at $3.70.
What is BriaCell Therapeutics Corp.'s business model?
The company operates as a clinical-stage biotechnology firm that generates revenue through the development of targeted immunotherapies. It focuses on harnessing the immune system to combat various cancers, particularly metastatic breast cancer, with its lead candidate Bria-IMT currently in Phase 3 trials. Additionally, BriaCell is working on personalized and next-generation immunotherapy platforms, which may provide future revenue streams.
What is the highest forecasted price for BCTX BriaCell Therapeutics Corp.?
Price targets from Wall Street analysts for BCTX are not currently available. The stock is trading at $3.70.
What is the lowest forecasted price for BCTX BriaCell Therapeutics Corp.?
Price targets from Wall Street analysts for BCTX are not currently available. The stock is trading at $3.70.
What is the overall BCTX consensus from analysts for BriaCell Therapeutics Corp.?
The overall analyst consensus for BCTX is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are BCTX stock price projections?
Stock price projections, including those for BriaCell Therapeutics Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 4:08 PM UTC